

## ASX Announcement



### Orthocell Investor Webinar Details

#### Quarter Ended 31 March 2026

**Perth, Australia; 14 April 2026:** Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) will announce its quarterly results for the period ended 31 March 2026 on Monday, 20 April 2026, and will also conduct a webinar on the same day. The webinar will provide an overview of the Company’s results along with an operational update, including the status of the US roll out of Remplir and its use in prostate cancer surgeries in Australia.

The webinar will be presented by Orthocell’s Chair, Mr John Van Der Wielen, CEO and Managing Director, Mr Paul Anderson, and CFO, Mr Jim Piper.

Details of the webinar are as follows:

#### Investor Briefing – Webinar

**When:** 9.00am AWST | 11.00am AEDST Monday 20 April 2026

**Register Now:** <https://Orthocell Ltd/Webinar/March Quarter/Register>

After registering, you will receive a confirmation email containing information about joining the webinar.

**Release authorised by:**

**Paul Anderson**

**Orthocell Ltd CEO and MD**

#### For more information, please contact:

##### General enquiries

**Paul Anderson**

Orthocell Limited  
CEO and MD

P: +61 8 9360 2888

E: [paul.anderson@orthocell.com](mailto:paul.anderson@orthocell.com)

##### Media enquiries

**Haley Chartres**  
H<sup>^</sup>CK Director

P: +61 423 139 163

E: [haley@hck.digital](mailto:haley@hck.digital)

##### Investor enquiries

**Shaun Duffy**  
VECTOR Advisors

P: +61 404 094 384

E: [sduffy@vectoradvisors.au](mailto:sduffy@vectoradvisors.au)

For personal use only

## About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit [www.orthocell.com](http://www.orthocell.com) or follow us on Twitter @OrthocellLtd and LinkedIn [www.linkedin.com/company/orthocell-ltd](http://www.linkedin.com/company/orthocell-ltd)

### Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.